Nautilus Biotech S.A.
Nautilus Biotech S.A., headquartered in France, is a pioneering company in the biotechnology sector, specialising in the development of innovative protein-based therapeutics. Founded in 2015, Nautilus has rapidly established itself as a leader in the biopharmaceutical industry, focusing on advanced drug discovery and development processes that leverage cutting-edge technologies. With a strong presence in Europe and expanding operations globally, Nautilus Biotech is renowned for its unique approach to protein engineering, which enhances the efficacy and safety of therapeutic proteins. The company’s core offerings include bespoke protein design and optimisation services, setting it apart in a competitive market. Nautilus has achieved significant milestones, including strategic partnerships and successful product launches, solidifying its position as a key player in the biotechnology landscape.
DitchCarbon Score
How does Nautilus Biotech S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nautilus Biotech S.A.'s score of 29 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Nautilus Biotech S.A.'s reported carbon emissions
Nautilus Biotech S.A., headquartered in France, currently does not report any specific carbon emissions data. However, the company has set ambitious climate commitments aimed at reducing greenhouse gas (GHG) emissions from its operations. Nautilus Biotech has pledged to achieve a 15% reduction in specific GHG emissions from its pulp and paper mills by 2030, using 2014 as the baseline year. This target applies to both Scope 1 and Scope 2 emissions, reflecting a comprehensive approach to mitigating its environmental impact. While no emissions data is available, these commitments demonstrate Nautilus Biotech's proactive stance on climate action and its dedication to sustainability within the industry. The company is focused on enhancing its operational efficiency and reducing its carbon footprint in alignment with global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nautilus Biotech S.A. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
